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Recessive dystrophic epidermolysis bullosa (RDEB) is a severe mechanobullous disease characterized 
at the molecular level by mutations in the COL7A1 gene, leading to reduced type VII collagen and 
defective anchoring fibrils at the dermal–epidermal junction (DEJ) (Fine et al., 2000). Patients who inherit 
this condition suffer from recurrent blistering, cutaneous ulcers, severe scarring, and deformities, 
and they are at high risk for developing life-threatening squamous cell carcinoma (Mallipeddi, 2002). 
Currently, there is no treatment for RDEB.
One approach to treatment would be to replace or reinforce the absent, reduced, or defective 
anchoring fibrils made up of type VII collagen, which would result in reduced blistering and ulceration. Among the current 
approaches under investigation are the use of gene therapy (Mavilio et al., 2006) and tissue-engineered skin (Falabella et al., 
1999). Although type VII collagen is largely secreted by keratinocytes, fibroblasts also participate in its production (Varki et al., 
2007; Goto et al., 2006). Recent studies have demonstrated that intradermal injections of normal human fibroblasts into affected 
mice resulted in the presence of persistent type VII human collagen (Ortiz-Urda et al., 2003; Woodley et al., 2007).
Stemming from these observations, Wong and colleagues (2008, this issue) report the first clinical experience in using 
allogeneic fibroblasts to treat RDEB. Each individual in a series of five patients with differing severities of RDEB received separate 
injections of cultured fibroblasts that were derived from their own skin (autologous), from a parent (allogeneic), and from an 
unrelated donor (allogeneic). Injection sites were assessed at 2 weeks and 3 months after injection. Described overall as safe and 
without adverse effects, the injection of allogeneic fibroblasts led to increased amounts of anchoring fibrils at both 2 weeks and 
3 months in patients with less severe forms of RDEB. Interestingly, the increase in type VII collagen appeared to be derived from 
the patient’s own cells as opposed to from donor fibroblasts.
Through the following questions, we examine this paper in greater detail. For brief answers, please refer to http://network.
nature.com/group/jidclub.
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QUESTIONS
1. What is the rationale for and what are the potential pitfalls of using allogeneic fibroblasts to treat RDEB?
2. Why were three different formulations of fibroblasts injected into subjects’ skin, and why was a sample taken at 2 weeks and 3 months?
3.  What data were presented that suggested utility of the modality, and was clinical improvement measured and correlated with 
histologic findings?
4.  Why might baseline immunostaining have predicted response at 3 months, and why did the injection of fibroblasts from unrelated 
donors produce better results than the injection of fibroblasts from related donors?
5. What are the potential mechanisms of action of allogeneic fibroblast injections?
6. What may be the clinical implications of this article?
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